# Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors

> **NCT00609765** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 1 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Avastin
- **DRUG:** Fluorouracil
- **DRUG:** Doxorubicin
- **DRUG:** Streptozocin
- **DRUG:** Dexamethasone
- **DRUG:** Ondansetron

## Key facts

- **NCT ID:** NCT00609765
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Development of new chemotherapy standard of care for treatment rendered the trial obsolete.
- **Last updated:** 2017-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00609765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00609765, "Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00609765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*